Are you getting the full picture?
The power of comprehensive intelligent diagnostics

Dr. Rena Callahan is a hematologist oncologist who practices in Santa Monica and Santa Clarita. As an associate clinical professor of medicine at the David Geffen school of medicine, she is active in the breast cancer research and treatment program. She is board certified in hematology and medical oncology.  Dr. Callahan is dedicated to providing patient-centered care, and including her patients in clinical decision making so that their individual goals are met. Dr. Callahan received her medical degree from the University of Pennsylvania School of Medicine, where she graduated Alpha Omega Alpha, with high honors. She completed her internal medicine and hematology/oncology training at UCLA. She received her Bachelor of Science degree in biology from Yale University.

Dr. Frank Weinberg is a physician and researcher in the Division of Hematology & Oncology at UI Health. As a medical oncologist, Dr. Weinberg is focused on providing the best care for lung cancer patients, utilizing a shared decision-making approach between the patient, family, other providers, nurses, and doctors. He uses the latest scientific research and approved medications to individualize care for each patient. In his research, Dr. Weinberg focuses on improving outcomes for patients undergoing immunotherapy, with a particular interest in advancing the understanding of cancer biology and metabolism. As a member of the University of Illinois Cancer Center, his contributions to these fields have led to important discoveries that inform clinical practice. Under his leadership, UI Health’s lung cancer immunotherapy trials are establishing new benchmarks in cancer treatment, further advancing the standard of care in this area.

Dr. Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus’ leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as Hematology/Oncology Fellowship Program Director.

Dr. Calvin Chao is the Senior Vice President of Medical Affairs at Tempus.  Previously, Dr. Chao spent thirteen years leading studies and education for the Oncotype DX Breast, Prostate, and Colon Cancer assays at Genomic Health, later acquired by Exact Sciences.  Prior to that role, he worked in various bio-pharmaceutical medical director positions at Onyx Pharmaceuticals, PDL BioPharma, TAP Pharmaceuticals, and SmithKline Beecham. In his early career, Dr. Chao practicedas a board-certified internist and hospitalist at Kaiser Permanente in California for ten years. He earned his MD from the University of Texas Medical Branch, completed his medical residency at Presbyterian-St. Luke’s Medical Center in Denver, Colorado, received his MBA from St. Mary’s College, California, and his BS in Chemical Engineering from University of California, Berkeley.

Dr. Kathleen Burke is a Senior Director of Computational Biology supporting the Tempus strategic alliances. This team collaborates across companies to drive multimodal analysis that accelerates projects throughout the discovery pipeline by enhancing trial design, broadening biomarker testing, investigating combination opportunities, identifying novel targets, and more. Before coming to Tempus, Kathleen worked at AstraZeneca in the bioinformatics group supporting the Early Oncology Translational Medicine, analyzing molecular data for Hematology drug teams with a focus on determining mechanisms of resistance to Acalabrutinib. She received her PhD in Biomedical Engineering from the University of Rochester and performed post-doctoral research at Memorial Sloan Kettering Cancer Center, understanding the genetic landscape of rare breast/uterine carcinomas.